Suppr超能文献

用吸血蝠唾液纤溶酶原激活剂对犬进行冠状动脉溶栓。通过静脉推注实现快速且持久的再通。

Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration.

作者信息

Witt W, Maass B, Baldus B, Hildebrand M, Donner P, Schleuning W D

机构信息

Department of Cardiovascular Pharmacology, Research Laboratories of Schering AG, Berlin, Germany.

出版信息

Circulation. 1994 Jul;90(1):421-6. doi: 10.1161/01.cir.90.1.421.

Abstract

BACKGROUND

DSPA (Desmodus salivary plasminogen activator) is a new thrombolytic agent corresponding to a natural plasminogen activator discovered in the saliva of the vampire bat Desmodus rotundus. Compared with tissue plasminogen activator (TPA), DSPA, produced in a recombinant cell line, is more fibrin cofactor dependent than TPA.

METHODS AND RESULTS

The thrombolytic properties of DSPA and TPA were compared in a canine model of copper coil-induced coronary thrombosis. All dogs received heparin 200 IU/kg IV and SC. Whereas controls did not reperfuse within 180 minutes (none of six), intravenous bolus administration of DSPA at 25, 50, and 100 micrograms/kg resulted in a 100% incidence (6 of 6) of recanalization within 37, 23, and 18 minutes, respectively. TPA at 63 and 125 micrograms/kg reopened the coronaries in 33% (two of six) and 50% (three of six) of cases within 40 minutes. Eighty-three percent (5 of 6) of the arteries were still patent 3 hours after 50 and 100 micrograms/kg DSPA, whereas only 20% (one of five) of all coronaries originally recanalized with both doses of TPA were still open at 3 hours. Plasma levels of alpha 2-antiplasmin decreased significantly only with 125 micrograms/kg TPA. The clearance of DSPA (2.3 to 3.5 mL.min-1.kg-1) was lower compared with TPA (11.4 to 20 mL.min-1.kg-1) due to a prolonged terminal half-life.

CONCLUSIONS

In a canine coronary thrombosis model, DSPA exhibited higher potency and recanalized coronary arteries faster and with a lower incidence of reocclusion than TPA. Its properties may translate into a higher efficacy in patients compared with available thrombolytic agents. The long half-life of DSPA may allow for single bolus administration in the treatment of acute myocardial infarction.

摘要

背景

吸血蝙蝠唾液纤溶酶原激活剂(DSPA)是一种新型溶栓剂,对应于在圆叶吸血蝠唾液中发现的一种天然纤溶酶原激活剂。与组织纤溶酶原激活剂(TPA)相比,在重组细胞系中产生的DSPA比TPA更依赖纤维蛋白辅因子。

方法与结果

在铜线圈诱导的犬冠状动脉血栓形成模型中比较了DSPA和TPA的溶栓特性。所有犬静脉内和皮下注射200 IU/kg肝素。对照组在180分钟内未再灌注(6只中无1只),静脉推注25、50和100微克/千克的DSPA分别在37、23和18分钟内导致再通发生率为100%(6只中的6只)。63和125微克/千克的TPA在40分钟内分别使33%(6只中的2只)和50%(6只中的3只)的冠状动脉再通。50和100微克/千克DSPA给药3小时后,83%(6只中的5只)的动脉仍保持通畅,而最初用两种剂量TPA再通的所有冠状动脉在3小时时只有20%(5只中的1只)仍开放。仅125微克/千克TPA使血浆α2-抗纤溶酶水平显著降低。由于终末半衰期延长,DSPA的清除率(2.3至3.5 mL·min-1·kg-1)低于TPA(11.4至20 mL·min-1·kg-1)。

结论

在犬冠状动脉血栓形成模型中,DSPA比TPA表现出更高的效力,冠状动脉再通更快且再闭塞发生率更低。与现有溶栓剂相比,其特性可能在患者中转化为更高的疗效。DSPA的长半衰期可能允许在急性心肌梗死治疗中单次推注给药。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验